New Synlight-Pure™ Kit together with Syncell’s Microscoop® Mint platform achieves high-specificity subcellular proteomic discovery with 25 ...
Australian patent strengthens global patent portfolio -bioAffinity Technologies, Inc. a biotechnology company advancing early-stage diagnostic...
Discovery and development of the first systemic therapeutics to deliver self-antigens directly to the thymus to harness the body’s natural mechanis...
siRNA candidate EMP-012 in phase I for treatment of COPD EMP-012 targets a distinct inflammatory pathway with enhanced potency and longer dose int...
Company highlights its global expertise and new and expanded capabilities to help biopharma and biotech customers solve global health challenges Thermo ...
Financing designed to support Phase 2 Parkinson’s trial and accelerate Nugevia™ product line growth Jupiter Neurosciences, Inc , a clinical...
Transaction strengthens neuroscience franchise for Novartis with three late-stage programs that address genetic neuromuscular diseases Advances the No...
First U.S. Surgical Treatments with PFA Clamp for Patients with Atrial Fibrillation During Concomitant Surgical Procedure -Pulse Biosciences, ...
SALVAT receives FDA approval for Clotic®, an innovative treatment for otomycosis with Orphan Drug Designation Th...
The U.S. Food and Drug Administration (FDA) has approved Gazyva® (obinutuzumab), developed by Genentech, as a treatment for adults with lupus n...
Adcytherix Raises EUR 105M Series A to Accelerate Breakthrough Antibody-Drug Conjugate Pipeline with Strategic Focus on Novel Payloads Financing led b...
Azurity Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved FerabrightTM (ferumoxytol injection), the first and...
Through this funding round, the company will initiate the clinical development of its first therapeutic candidate, EVerGel, in 2026, and will enhance its...
-Corventum, Inc., a new medicines company advancing novel therapies to make existing cancer treatments safer and more effective, announced the clea...
© 2025 Biopharma Boardroom. All Rights Reserved.
